INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Exclusion Criteria

• •Received prior treatment with checkpoint inhibitor agents (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4).
• •Had major surgery within 3 weeks before the first dose of study treatment.
• •Received radiation therapy to the lung(s) that is \> 30 Gy within 6 months of the first dose of study treatment.
• •Received palliative radiotherapy within 7 days before the first dose of study treatment.
• •Has ≥ Grade 2 residual toxicities from the most recent prior therapy (except alopecia).
• •Organ function (renal, hepatic), bone marrow reserve, and coagulation panel outside the protocol-defined laboratory values.
• •Is currently participating and receiving investigational therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks before the first dose of study treatment.
• •Has active autoimmune disease requiring systemic immunosuppression with corticosteroids (\> 10 mg once daily of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment.
• •Is on chronic systemic steroids (\> 10 mg once daily of prednisone or equivalent).
• •Known active central nervous system metastases and/or carcinomatous meningitis (patients with previously-treated and clinically stable brain metastases are eligible and a washout period of ≥ 4 weeks since radiation therapy is required).
• •Known additional malignancy that is progressing or requires active treatment.
• •Evidence of interstitial lung disease or active, noninfectious pneumonitis.
• •History of organ transplant, including allogeneic stem cell transplantation.
• •Active infections requiring systemic antibiotics.
• •Known active hepatitis B or C.
• •Has a diagnosis of immunodeficiency, including participants known to be HIV positive (positive for HIV 1/2 antibodies).
• •Significant cardiac event within 6 months before Cycle 1 Day 1.
• •Has received a live vaccine within 28 days of the planned start of study treatment.
• •Known hypersensitivity to any component of the study drugs, excipients, or another monoclonal antibody which cannot be controlled with standard measures (eg, antihistamines and corticosteroids).